type
sm-banner
background-image
eyebrow
A Real Economy publication
title
2026 life sciences industry outlook
date
April 29, 2026
text-color
light
gradient-overlay
dark
breadcrumb
Key takeaways
Divergent U.S. and UK timelines require tailored clinical trial design and funding.
Private and mid-cap medtech firms are driving more trials and approvals as innovation pathways shift.
Capital constraints and regulatory complexity are reshaping where and how devices are developed.
TREND: Medtech innovation is shifting
As medtech innovation continues to shift, companies will need to be more deliberate in how they invest in, develop and bring new devices to market. Medtech companies should prioritize capital efficiency, portfolio focus and strategic trials rather than simply increasing R&D levels.
TREND: Clinical trial timelines in flux
As clinical trial timelines compress in the U.S. and lengthen in the UK, life sciences companies should proactively tailor trial design, geography and funding strategies to each market’s realities.